Psyence Biomedical Ltd Stock Current Valuation
| PBM Stock | USD 3.46 0.05 1.42% |
Valuation analysis of Psyence Biomedical helps investors to measure Psyence Biomedical's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of the 1st of December 2024, Enterprise Value Over EBITDA is likely to drop to -216.34. In addition to that, Enterprise Value Multiple is likely to drop to -216.34. Fundamental drivers impacting Psyence Biomedical's valuation include:
Enterprise Value 12.3 M |
Overvalued
Today
Please note that Psyence Biomedical's price fluctuation is dangerous at this time. Calculation of the real value of Psyence Biomedical is based on 3 months time horizon. Increasing Psyence Biomedical's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Psyence stock is determined by what a typical buyer is willing to pay for full or partial control of Psyence Biomedical Ltd. Since Psyence Biomedical is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Psyence Stock. However, Psyence Biomedical's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.46 | Real 3.04 | Hype 4.27 | Naive 4.12 |
The intrinsic value of Psyence Biomedical's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Psyence Biomedical's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Psyence Biomedical Ltd helps investors to forecast how Psyence stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Psyence Biomedical more accurately as focusing exclusively on Psyence Biomedical's fundamentals will not take into account other important factors: Psyence Biomedical Ltd Company Current Valuation Analysis
Psyence Biomedical's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Psyence Biomedical Current Valuation | 12.32 M |
Most of Psyence Biomedical's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Psyence Biomedical Ltd is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Psyence Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Psyence Biomedical is extremely important. It helps to project a fair market value of Psyence Stock properly, considering its historical fundamentals such as Current Valuation. Since Psyence Biomedical's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Psyence Biomedical's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Psyence Biomedical's interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Psyence Biomedical Ltd has a Current Valuation of 12.32 M. This is 99.91% lower than that of the Biotechnology sector and 99.73% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.93% higher than that of the company.
Psyence Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Psyence Biomedical's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Psyence Biomedical could also be used in its relative valuation, which is a method of valuing Psyence Biomedical by comparing valuation metrics of similar companies.Psyence Biomedical is currently under evaluation in current valuation category among its peers.
Psyence Fundamentals
| Return On Asset | -1.26 | ||||
| Current Valuation | 12.32 M | ||||
| Shares Outstanding | 16.7 M | ||||
| Shares Owned By Insiders | 58.48 % | ||||
| Shares Owned By Institutions | 13.24 % | ||||
| Number Of Shares Shorted | 823.87 K | ||||
| EBITDA | (2.75 M) | ||||
| Net Income | (51.16 M) | ||||
| Cash And Equivalents | 281.63 K | ||||
| Cash Per Share | 0.02 X | ||||
| Total Debt | 10.45 M | ||||
| Current Ratio | 7.95 X | ||||
| Book Value Per Share | (0.82) X | ||||
| Cash Flow From Operations | (2.95 M) | ||||
| Short Ratio | 0.71 X | ||||
| Earnings Per Share | (7.82) X | ||||
| Beta | -0.36 | ||||
| Market Capitalization | 2.6 M | ||||
| Total Asset | 1.13 M | ||||
| Retained Earnings | (57.46 M) | ||||
| Working Capital | (10.98 M) | ||||
| Current Asset | 327 K | ||||
| Current Liabilities | 42 K | ||||
| Net Asset | 1.13 M |
About Psyence Biomedical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Psyence Biomedical Ltd's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Psyence Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Psyence Biomedical Ltd based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Psyence Biomedical Piotroski F Score and Psyence Biomedical Altman Z Score analysis. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Psyence Biomedical. If investors know Psyence will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Psyence Biomedical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.82) | Return On Assets (1.26) |
The market value of Psyence Biomedical is measured differently than its book value, which is the value of Psyence that is recorded on the company's balance sheet. Investors also form their own opinion of Psyence Biomedical's value that differs from its market value or its book value, called intrinsic value, which is Psyence Biomedical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Psyence Biomedical's market value can be influenced by many factors that don't directly affect Psyence Biomedical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Psyence Biomedical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Psyence Biomedical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Psyence Biomedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.